CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
IPO Year: 2016
Exchange: NASDAQ
Website: crisprtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $60.00 → $99.00 | In-line → Outperform | Evercore ISI |
| 2/12/2025 | $35.00 | Sell → Hold | TD Cowen |
| 2/3/2025 | $65.00 | Buy | H.C. Wainwright |
| 8/6/2024 | $88.00 → $84.00 | Buy | Needham |
| 8/2/2024 | $90.00 | Buy | Rodman & Renshaw |
| 6/28/2024 | Neutral | Guggenheim | |
| 2/15/2024 | Peer Perform | Wolfe Research | |
| 12/11/2023 | $30.00 | Market Perform → Underperform | TD Cowen |
| 10/17/2023 | Overweight → Neutral | Cantor Fitzgerald | |
| 9/27/2023 | $82.00 | Buy | Mizuho |
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- -CASGEVY® continues to gain momentum; more than 65 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 90 patients have had cells collected across all regions; new patient initiations expected to grow significantly in 2025- -Clinical trial ongoing for CTX320™, targeting the LPA gene; top-line data update on track for the second quarter of 2025- -Clinic
ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR Therapeutics Since its ince
ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025. "Julie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfully advancing our hematology and oncology programs, as well as several important cross-functional initiatives to mature our operating model," said Samarth Kulkarni, Ph.D., Chairman and Ch
ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR TherapeuticsSince its inc
-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 50 patients have had cells collected across all regions as of the end of 2024- -Clinical trials ongoing for next-generation CAR T product candidates, CTX112™ and CTX131™, targeting CD19 and CD70 across multiple indications; updates for CTX112 in oncology and autoimmune diseases are expected in mid-2025 with CTX131 updates expected in 2025- -CRISPR Therapeutics and Nkure Thera
ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 2:00 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR TherapeuticsSince its inc
-Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated 2025 milestones. "As we look ahead to 2025, we are in a privileged position with an approved commercial product, a rich pipeline, a strong balance sheet and an o
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation. About CRISPR The
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company's annual general meeting to be held this year. "We are excited to welcome Briggs to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. "His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pip
-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for the treatment of certain relapsed or refractory (R/R) CD19-positive B-cell malignancies- -CTX112 is also in a Phase 1 clinical trial in systemic lupus erythematosus (SLE), with the potential to expand into additional autoimmune indications in the future- -Company expects to provide a broader update across oncology and autoimmune indications in mid-2025- ZUG, Switze
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G - CRISPR Therapeutics AG (0001674416) (Subject)
SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
Evercore ISI upgraded CRISPR Therapeutics from In-line to Outperform and set a new price target of $99.00 from $60.00 previously
TD Cowen upgraded CRISPR Therapeutics from Sell to Hold and set a new price target of $35.00
H.C. Wainwright initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $65.00
Needham reiterated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $84.00 from $88.00 previously
Rodman & Renshaw initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $90.00
Guggenheim resumed coverage of CRISPR Therapeutics with a rating of Neutral
Wolfe Research initiated coverage of CRISPR Therapeutics with a rating of Peer Perform
TD Cowen downgraded CRISPR Therapeutics from Market Perform to Underperform and set a new price target of $30.00
Cantor Fitzgerald downgraded CRISPR Therapeutics from Overweight to Neutral
Mizuho initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $82.00
-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six-month CR rate of 21% and longest response on-going at over 18 months after initial infusion- -Response rates and durability are similar to approved autologous CD19 CAR-T therapies on an ITT basis- -Positively differentiated safety profile; no Grade 3 or higher cytokine release syndrome (CRS) and low rates of infection and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)- -Expanding CARBON into a potentially registrational trial in 1Q 20
-Management to host conference call and webcast on October 12th at 4:30 p.m. ET- ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. Conference Call and Web
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company's annual general meeting to be held this year. "We are excited to welcome Briggs to our Board of Directors," said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics. "His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pip
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company al
ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities. "I'm excited to welcome Raju to our leadership team," said Samarth Kulkarni, Ph.D., Chief Exec
ZUG, Switzerland and BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023. Dr. Harding brings extensive leadership experience in biopharma business development and corporate strategy and joins CRISPR Therapeutics to lead the Company's business development operations. "Alex's broad-based experience in strategic business development, venture formation and platform expansion will be critical in driving the next phase
ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., FACP, as Chief Medical Officer, effective May 23, 2022. Dr. Morrow brings more than a decade of leadership experience in global drug development and joins CRISPR Therapeutics to lead the Company's global clinical development and regulatory operations. "P.K.'s leadership experience, deep expertise in oncology drug development, and her track record in bringing novel medicines to patients will be invaluable as we c
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr. Smith brings more than 20 years of financial, operational and strategic leadership experience, including as CFO of Translate Bio. He succeeds Michael Tomsicek, who is retiring after four years of service to the Company. It is expected that Mr. Tomsicek will remain with the Company in an advisory role through the end of 2021 to help ensure a smooth transition. "I'm excited to welcome
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Philippe Drouet as Chief Commercial Officer. Mr. Drouet brings more than 20 years of leadership experience in global pharmaceutical marketing and joins CRISPR Therapeutics to develop and oversee the Company’s global commercialization efforts. “Philippe’s experience in building and leading global commercial organizations, and his track record of successfully launching a range of leading oncology and hematology brands, will be critical in driv
10-Q - CRISPR Therapeutics AG (0001674416) (Filer)
8-K - CRISPR Therapeutics AG (0001674416) (Filer)
DEFA14A - CRISPR Therapeutics AG (0001674416) (Filer)
DEF 14A - CRISPR Therapeutics AG (0001674416) (Filer)
PRE 14A - CRISPR Therapeutics AG (0001674416) (Filer)
8-K - CRISPR Therapeutics AG (0001674416) (Filer)
10-K - CRISPR Therapeutics AG (0001674416) (Filer)
8-K - CRISPR Therapeutics AG (0001674416) (Filer)
10-Q - CRISPR Therapeutics AG (0001674416) (Filer)
8-K - CRISPR Therapeutics AG (0001674416) (Filer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)